TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Overall satisfaction with the procedure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recommendation of IUD to a friend
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Perception of IUD worth the discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bleeding rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral blood eosinophil numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical success assessed by PGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mortality due to infection
Endpoint domain: Mortality/survival
Primary endpoint: catheter associated infection
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Unit cost of EIMC using AccuCirc compared to Mogen clamp
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: weight-for-length z scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antichlamydial antibodies concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean anxiety scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of MSI positive cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Giving-way frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant birthweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported improvement in specific functional tasks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum EL concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: beta-cell secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Post-baseline keratopathy
Endpoint domain: Adverse events/effects
Primary endpoint: Mild post-baseline retinal findings
Endpoint domain: Adverse events/effects
Primary endpoint: Visual field sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serological cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improved effect measures for medical behaviour
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cross sectional areas (CSA1, CSA2, CSA3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal cavity volumes (V1, V2, V3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIHSS scores at 90 days post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mRS scores at 90 days post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anti-HBs GMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SP rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: lifetime cannabis use disorder (CUD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Teaching effectiveness of HPS vs CBL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: quality-of-life assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean visual analogue pain scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Early bronchial clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Uptake rates of HIV testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in dizziness symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triglyceridemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VLDL TG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in steroids dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H. pylori negative status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete symptom relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of PTSD diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerability of Dynamiclear formulation
Endpoint domain: Adverse events/effects
Primary endpoint: hematological and biochemical markers within normal range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic management of HSV‐1 and HSV‐2 lesions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Volume required for treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of touch-ups required
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Injection pain reported
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in E/CO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ventilation at peak exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cold Sensory Threshold (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone loss at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum zonulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Walking capacity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 60-day mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: Cardiovascular complications in the postoperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient discomfort associated with nasogastric tube passage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearance of solutes and removal of β2M
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction rates of urea, creatinine, and β2M
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional indices (WOMAC score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutamate levels in the associative striatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interval from administration of drug to initiation of uterine contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in tender joint count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in swollen joint count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HR response to tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of nightmare
Endpoint domain: Adverse events/effects
Primary endpoint: Mean temperature increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal heart rate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypertrophic scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Scar color acceptability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain relief achieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective dose of ≥600 µg attained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: zLCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of AL (Air Leak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative hospitalization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total foot peak pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lateral forefoot FTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lateral forefoot normalised maximum force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum C‐peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: symptomatic hypoglycemia episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in drop-seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: hs-TnI levels at rest and during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to first bowel movement (BM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Need for magnesium citrate to initiate bowel movement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Calcaneal BUA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in laryngoscopic view grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma metabolome variance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Balance times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived risk of water speeds
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Atherosclerotic plaque inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High-density lipoprotein cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SCr level improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Annual decline in FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lightening of post-inflammatory hyperpigmented lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Epidermal melanin content decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Average annual total cost of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Interobserver and intraobserver reliability for grading MRI parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean postoperative pain relief at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragm-paced tidal volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration without mechanical ventilators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration of remission
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Identification of Chlamydia and HSV 2 infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Skeletal, dentoalveolar and soft tissue changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall success rates of inferior alveolar nerve block anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in Scr at 72 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Occurrence of gastrointestinal cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement of gastric mucosal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of abortion 24 hours after initiation of treatment
Endpoint domain: Mortality/survival
Primary endpoint: Rate of abortion 48 hours after initiation of treatment
Endpoint domain: Mortality/survival
Primary endpoint: knowledge retention regarding the IVFA procedure
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Duration of continuous abstinence from cocaine
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of cocaine-negative urine samples during treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Duration of operative treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of supragingival calculus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in nonfasting triglyceride (TG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AFP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CSF level of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MDNS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MNSI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: enhanced recognition for high-reward pictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maternal weight gain during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum magnesium levels within target levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monthly volunteering minutes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of new lesions on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: optotype visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of complications
Endpoint domain: Adverse events/effects
Primary endpoint: change in MADRS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of patients showing no side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Aspergillus infection
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of invasive disease
Endpoint domain: Adverse events/effects
Primary endpoint: Intensity of withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carriage of vaccine serotypes (VT) pneumococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Acquisition rate of non-vaccine serotypes (NVT) pneumococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quadriceps MVIC decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protection against endometrial hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in endometrial bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in health-related quality-of-life measures
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pulse Wave Velocity (PWV) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum parathyroid hormone change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum calcium change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mammary tissue concentrations of 4‐OHT, endoxifen, and telapristone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Échelle d'Évaluation Clinique Des Cicatrices d'Acné scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Postinflammatory hyperpigmentation (PIH)
Endpoint domain: Adverse events/effects
Primary endpoint: Pap smear utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in constructive problem-solving styles
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of new pressure ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: P wave duration reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in HRR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vaccine virus shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rise in serum neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increased RSV antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Weaning from CPB in the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in glabellar frown lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival rate in cardiovascular morbidity
Endpoint domain: Mortality/survival
Primary endpoint: total homocysteine plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean eye level blood pressure (ELBP) at syncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long-term quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MGYSS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of BMD loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemotherapy response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Harvested CD34+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of patients with sufficient material for autologous bone marrow transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hematopoietic recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Failure of SN to predict axillary histologic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: percentage of goal EN delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: recurrence rate of CIN1/2/3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in Leeds revised acne grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Expression of caspase‐3 and caspase‐9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of specific IgG(Mite)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum levels of specific IgG4(Mite)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: urinary 8‐iso‐PGF(2alpha) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Objective clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: PTHrP secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 10-year survival rate of FDPs
Endpoint domain: Mortality/survival
Primary endpoint: 10-year survival rate for zirconia frameworks
Endpoint domain: Mortality/survival
Primary endpoint: complication rate of chipping/fracture of veneering ceramic
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Global Assessment improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean percent change in BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean time to therapeutic INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in therapeutic INR range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer patients with INRs >4.5
Endpoint domain: Adverse events/effects